NSAI treatment — Competitive Intelligence Brief

NSAI treatment (NSAI treatment) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nonsteroidal anti-inflammatory drug (NSAID). Area: Inflammation, Pain Management.

marketed Nonsteroidal anti-inflammatory drug (NSAID) Cyclooxygenase (COX-1 and/or COX-2) Inflammation, Pain Management Small molecule

Target snapshot

NSAI treatment (NSAI treatment) — London School of Hygiene and Tropical Medicine. NSAI treatment inhibits nonsteroidal anti-inflammatory agents to reduce inflammation and associated symptoms.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
NSAI treatment TARGET	NSAI treatment	London School of Hygiene and Tropical Medicine	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	Cyclooxygenase (COX-1 and/or COX-2)
Topical Diclofenac gel 1%	Topical Diclofenac gel 1%	University of California, Davis	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	COX-1 and COX-2
Ibuprofen group	Ibuprofen group	University of Salamanca	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	COX-1, COX-2
Loxoprofen sodium hydrogel patch	Loxoprofen sodium hydrogel patch	Sun Yat-sen University	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	Cyclooxygenase (COX-1 and COX-2)
Acetylsalicylic Acid (ASA)	Acetylsalicylic Acid (ASA)	Sunnybrook Health Sciences Centre	marketed	Nonsteroidal anti-inflammatory drug (NSAID); antiplatelet agent	Cyclooxygenase-1 (COX-1); Cyclooxygenase-2 (COX-2)
High Dose Ibuprofen	High Dose Ibuprofen	Ottawa Hospital Research Institute	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	COX-1 and COX-2
aspirin (ASA)	aspirin (ASA)	Janssen Scientific Affairs, LLC	marketed	Nonsteroidal anti-inflammatory drug (NSAID); antiplatelet agent	Cyclooxygenase-1 (COX-1); Cyclooxygenase-2 (COX-2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nonsteroidal anti-inflammatory drug (NSAID) class)

1. Università degli Studi di Brescia · 4 drugs in this class
2. Bausch & Lomb Incorporated · 4 drugs in this class
3. Bayer · 3 drugs in this class
4. Pfizer · 3 drugs in this class
5. Azienda USL Reggio Emilia - IRCCS · 3 drugs in this class
6. Organon and Co · 3 drugs in this class
7. Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division · 2 drugs in this class
8. Bezmialem Vakif University · 2 drugs in this class
9. Guang'anmen Hospital of China Academy of Chinese Medical Sciences · 2 drugs in this class
10. Center For Excellence In Eye Care · 2 drugs in this class